EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia

Yuri L Sosero, Sara Bandres-Ciga iD, Bart Ferwerda, Maria T P Tocino, Dìaz R Belloso, Pilar Gómez-Garre iD, Johann Faouzi, Pille Taba, Lukas Pavelka, Tainà M Marques, Clarissa P C Gomes, Alexey Kolodkin und 27 weitere

Movement Disorders · 2024

DOI: 10.1002/mds.29960 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2024. Verfasst von Yuri L Sosero und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, McGill University, Montréal, Canada. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Dyskinesia, Drug-Induced, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, NINDS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Levodopa‐induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2 .

Objectives

Our goal was to investigate the effects of genetic variants on risk and time to LID.

Methods

We performed a genome‐wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID.

Results

We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95% confidence interval [CI], 1.21–2.26; P = 0.0017) and LRRK2 variants with reduced time to LID onset (hazard ratio [HR] = 1.42; 95% CI, 1.09–1.84; P = 0.0098). The fourth quartile of the PD PRS was associated with increased LID risk (OR fourth_quartile = 1.27; 95% CI, 1.03–1.56; P = 0.0210). The third and fourth dopamine pathway PRS quartiles were associated with a reduced time to development of LID (HR third_quartile = 1.38; 95% CI, 1.07–1.79; P = 0.0128; HR fourth_quartile = 1.38; 95% CI = 1.06–1.78; P = 0.0147).

Conclusions

This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseDyskinesia, Drug-InducedLeucine-Rich Repeat Serine-Threonine Protein Kinase-2GlucosylceramidaseGenome-Wide Association StudyHumansMaleFemaleAgedMiddle AgedDopamineAntiparkinson AgentsGenetic Predisposition to DiseasePolymorphism, Single Nucleotide

Stichwörter der Autor:innen

GBA1LRRK2Parkinson's diseasedopaminelevodopa‐induced dyskinesia

Substanzen

LevodopaLeucine-Rich Repeat Serine-Threonine Protein Kinase-2GlucosylceramidaseLRRK2 protein, humanDopamineGBA protein, humanAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Human Genetics, McGill University, Montréal, Canada.
  • Department of Neurology, The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montréal, Canada.
  • Department of Health and Human Services, Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes on Health, Bethe…
  • Department of Clinical Epidemiology and Biostatistics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Servicio de Neurología y Neurofisiología Clínica, Unidad de Trastornos del Movimiento, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
  • Department of Neurobiology, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.

ORCID-Profile: Sara Bandres-Ciga, Pilar Gómez-Garre, Patrick May, Zbigniew K Wszolek, David K Simon, Owen A Ross, Jean-Christophe Corvol, Sulev Koks, Pablo Mir, Rob M A De Bie, Hirotaka Iwaki, Ziv Gan-Or

Förderung

  • Intramural NIH HHS
  • NINDS NIH HHS
  • NIA NIH HHS
  • Wellcome Trust
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Sosero, Y. L., Bandres-Ciga, S., Ferwerda, B., Tocino, M. T. P., Belloso, D. R., Gómez-Garre, P., Faouzi, J., Taba, P., Pavelka, L., Marques, T. M., Gomes, C. P. C., Kolodkin, A., May, P., Milanowski, L. M., Wszolek, Z. K., Uitti, R. J., Heutink, P., van Hilten, J. J., Simon, D. K., …, & International Parkinson's Disease Genomic Consortium (2024). Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia. Movement Disorders. https://doi.org/10.1002/mds.29960

Vancouver

Sosero YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, Belloso DR, Gómez-Garre P, et al. Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia. Movement Disorders. 2024. doi:10.1002/mds.29960

BibTeX
@article{Sosero2024,
  author = {Sosero, Yuri L and Bandres-Ciga, Sara and Ferwerda, Bart and Tocino, Maria T P and Belloso, Dìaz R and Gómez-Garre, Pilar and Faouzi, Johann and Taba, Pille and Pavelka, Lukas and Marques, Tainà M and Gomes, Clarissa P C and Kolodkin, Alexey and May, Patrick and Milanowski, Lukasz M and Wszolek, Zbigniew K and Uitti, Ryan J and Heutink, Peter and van Hilten, Jacobus J and Simon, David K and Eberly, Shirley and Alvarez, Ignacio and Krohn, Lynne and Yu, Eric and Freeman, Kathryn and Rudakou, Uladzislau and Ruskey, Jennifer A and Asayesh, Farnaz and Menéndez-Gonzàlez, Manuel and Pastor, Pau and Ross, Owen A and Krüger, Rejko and NCER‐PD Consortium, NCER‐PD Consortium and Corvol, Jean-Christophe and Koks, Sulev and Mir, Pablo and De Bie, Rob M A and Iwaki, Hirotaka and Gan-Or, Ziv and International Parkinson's Disease Genomic Consortium, International Parkinson's Disease Genomic Consortium},
  title = {Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia},
  journal = {Movement Disorders},
  year = {2024},
  doi = {10.1002/mds.29960}
}
Kostenlos starten →